Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Símbolo de cotizaciónVOR
Nombre de la empresaVor Biopharma Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Jean-Paul Kress, M.D.
Número de empleados159
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección100 Cambridgepark Drive
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Teléfono16176556580
Sitio Webhttps://www.vorbio.com/
Símbolo de cotizaciónVOR
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Jean-Paul Kress, M.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos